Dose prescription and optimisation based on tumour hypoxia

Acta Oncologica

Volumn 48, Issue 8, 2009, Pages 1181-1192

  Toma Daşu, Iuliana ^a   Daşu, Alexandru ^b   Brahme, Anders ^a  

^a STOCKHOLM UNIVERSITY   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

Oxygenation; PET imaging; Treatment optimization; Tumour oxygenation; Vasculature

Indexed keywords

ARTICLE; CANCER CONTROL; CELL HETEROGENEITY; HYPOXIA; IMAGING; OXYGENATION; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIOSENSITIVITY; TUMOR;

CELL HYPOXIA; COMPUTER SIMULATION; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; OXYGEN; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; TREATMENT OUTCOME;

EID: 70350787198     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/02841860903188643     Document Type: Article

References (65)

1. Hö ckel M, Knoop C, Schlenger K, Vorndran B, Baussmann E, Mitze M, et al. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993;/26:/45-50.
2. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;/41:/31-9.
3. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999;/53:/113-7.
4. Hö ckel M, Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol 2001;/28:/36-41.
5. Fyles A, Milosevic M, Hedley D, Pintilie M, Levin W, Manchul L, et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 2002;/20:/680-7.
6. Carnell DM, Smith RE, Daley FM, Saunders MI, Bentzen SM, Hoskin PJ. An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: Implications for radioresistance. Int J Radiat Oncol Biol Phys 2006;/ 65:/91-9.
7. Hall EJ, Giaccia AJ. Radiobiology for the radiologist, 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2006.
8. Watson ER, Halnan KE, Dische S, Saunders MI, Cade IS, McEwen JB, et al. Hyperbaric oxygen and radiotherapy: A Medical Research Council trial in carcinoma of the cervix. Br J Radiol 1978;/51:/879-87. (Pubitemid 9033490)
9. Saunders MI, Hoskin PJ, Pigott K, Powell ME, Goodchild K, Dische S, et al. Accelerated radiotherapy, carbogen and nicotinamide (ARCON) in locally advanced head and neck cancer: A feasibility study. Radiother Oncol 1997;/45:/ 159-66.
10. Kaanders JH, Pop LA, Marres HA, Liefers J, van den Hoogen FJ, van Daal WA, et al. Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer. Radiother Oncol 1998;/48:/115-22.
11. Dische S. Chemical sensitizers for hypoxic cells: A decade of experience in clinical radiotherapy. Radiother Oncol 1985;/3:/ 97-115.
12. Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res 1994;/6:/ 509-18.
13. Overgaard J, Horsman MR. Modification of Hypoxiainduced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 1996;/6:/10-21.
14. Fowler JF. Nuclear particles in cancer treatment. Bristol: Adam Hilger Ltd.; 1981.
15. Brahme A. Recent advances in light ion radiation therapy. Int J Radiat Oncol Biol Phys 2004;/58:/603-16.
16. Lind BK, Brahme A. The radiation response of heterogeneous tumors. Phys Med 2007;/23:/91-9.
17. Daşu A, Toma-Daşu I. Vascular oxygen content and the tissue oxygenation-a theoretical analysis. Med Phys 2008;/ 35:/539-45.
18. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med 2008;/49(Suppl 2):/129S-148.
19. Ling CC, Humm J, Larson S, Amols H, Fuks Z, Leibel S, et al. Towards multidimensional radiotherapy (MD-CRT): Biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000;/47:/551-60.
20. Tome WA, Fowler JF. On the inclusion of proliferation in tumour control probability calculations for inhomogeneously irradiated tumours. Phys Med Biol 2003;/48:/N261-8.
21. Chao KSC, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA, et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2001;/49:/ 1171-82.
22. Grosu AL, Souvatzoglou M, Roper B, Dobritz M, Wiedenmann N, Jacob V, et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007;/69:/ 541-51.
23. Lee ST, Scott AM. Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole. Semin Nucl Med 2007;/37:/451-61.
24. Xing L, Cotrutz C, Hunjan S, Boyer AL, Adalsteinsson E, Spielman D. Inverse planning for functional image-guided intensity-modulated radiation therapy. Phys Med Biol 2002;/ 47:/3567-78.
25. Alber M, Paulsen F, Eschmann SM, Machulla HJ. On biologically conformal boost dose optimization. Phys Med Biol 2003;/48:/N31-5.
26. Das SK, Miften MM, Zhou S, Bell M, Munley MT, Whiddon CS, et al. Feasibility of optimizing the dose distribution in lung tumors using fluorine-18-fluorodeoxyglucose positron emission tomography and single photon emission computed tomography guided dose prescriptions. Med Phys 2004;/31:/1452-61.
27. Malinen E, Sovik A, Hristov D, Bruland OS, Olsen DR. Adapting radiotherapy to hypoxic tumours. Phys Med Biol 2006;/51:/4903-21.
28. Søvik A, Malinen E, Bruland OS, Bentzen SM, Olsen DR. Optimization of tumour control probability in hypoxic tumours by radiation dose redistribution: A modelling study. Phys Med Biol 2007;/52:/499-513.
29. Flynn RT, Bowen SR, Bentzen SM, Rockwell MT, Jeraj R. Intensity-modulated x-ray (IMXT) versus proton (IMPT) therapy for theragnostic hypoxia-based dose painting. Phys Med Biol 2008;/53:/4153-67.
30. Koh WJ, Bergman KS, Rasey JS, Peterson LM, Evans ML, Graham MM, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 1995;/33:/391-8.
31. Roels S, Slagmolen P, Nuyts J, Lee JA, Loeckx D, Maes F et al. Biological image-guided radiotherapy in rectal cancer: Is there a role for FMISO or FLT, next to FDG? Acta Oncol 2008;/47:/1237-48.
32. Thorwarth D, Eschmann SM, Paulsen F, Alber M. Hypoxia dose painting by numbers: A planning study. Int J Radiat Oncol Biol Phys 2007;/68:/291-300.
33. Brahme A. Biologically optimized 3-dimensional in vivo predictive assay-based radiation therapy using positron emission tomography-computerized tomography imaging. Acta Oncol 2003;/42:/123-36.
34. Douglas BG, Fowler JF. Fractionation schedules and a quadratic dose-effect relationship. Br J Radiol 1975;/48:/ 502-4.
35. Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys 1982;/8:/1981-97.
36. Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989;/62:/679-94.
37. Alper T, Howard-Flanders P. Role of oxygen in modifying the radiosensitivity of E. Coli B. Nature 1956;/178:/978-9.
38. Alper T. Cellular radiobiology. Cambridge: Cambridge University Press; 1979.
39. Thames HD, Bentzen SM, Turesson I, Overgaard M, Van den Bogaert W. Time-dose factors in radiotherapy: A review of the human data. Radiother Oncol 1990;/19:/219-35.
40. A°gren Cronqvist AK, Kallman P, Turesson I, Brahme A. Volume and heterogeneity dependence of the dose-response relationship for head and neck tumours. Acta Oncol 1995;/ 34:/851-60.
41. Brahme A, .A° gren AK. Optimal dose distribution for eradication of heterogeneous tumours. Acta Oncol 1987;/26:/ 377-85.
42. Ljungkvist ASE, Bussink J, Rijken PFJW, Kaanders JHAM, van der Kogel AJ, Denekamp J. Vascular architecture, hypoxia, and proliferation in first-generation xenografts of human head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2002;/54:/215-28.
43. Daşu A, Toma-Daşu I, Karlsson M. Theoretical simulation of tumour oxygenation and results from acute and chronic hypoxia. Phys Med Biol 2003;/48:/2829-42.
44. Kelly CJ, Brady M. A model to simulate tumour oxygenation and dynamic [18F]-Fmiso PET data. Phys Med Biol 2006;/ 51:/5859-73.
45. Brahme A. Dosimetric precision requirements and quantities for characterizing the response of tumors and normal tissues. IAEA-TECDOC 1996;/896:/49-65.
46. Brahme A. Dosimetric precision requirements in radiation therapy. Acta Radiol Oncol 1984;/23:/379-91.
47. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res 1989;/49:/6449-65.
48. Daşu A, Toma-Daşu I. Theoretical simulation of tumour oxygenation- practical applications. Adv Exp Med Biol 2006;/578:/357-62.
49. Toma-Daşu I, Daşu A, Brahme A. Quantifying tumour hypoxia by PET imaging- a theoretical analysis. Adv Exp Med Biol 2009;/645:/267-72.
50. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OCA. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953;/ 26:/638-48.
51. Overgaard J. Hypoxic radiosensitization: Adored and ignored. J Clin Oncol 2007;/25:/4066-74.
52. Chaplin DJ, Olive PL, Durand RE. Intermittent blood flow in a murine tumor: Radiobiological effects. Cancer Res 1987;/47:/597-601.
53. Bussink J, Kaanders JHAM, Rijken PFJW, Peters JPW, Hodgkiss RJ, Marres HAM, et al. Vascular architecture and microenvironmental parameters in human squamous cell carcinoma xenografts: Effects of carbogen and nicotinamide. Radiother Oncol 1999;/50:/173-83.
54. Rijken PFJW, Bernsen HJJA, Peters JPW, Hodgkiss RJ, Raleigh JA, van der Kogel AJ. Spatial relationship between hypoxia and the (perfused) vascular network in a human glioma xenograft: A quantitative multi-parameter analysis. Int J Radiat Oncol Biol Phys 2000;/48:/571-82.
55. Eschmann SM, Paulsen F, Bedeshem C, Machulla HJ, Hehr T, Bamberg M, et al. Hypoxia-imaging with (18)FMisonidazole and PET: Changes of kinetics during radiotherapy of head-and-neck cancer. Radiother Oncol 2007;/83:/ 406-10.
56. Chapman JD. The detection and measurement of hypoxic cells in solid tumors. Cancer 1984;/54:/2441-9.
57. Toma-Daşu I, Uhrdin J, Daşu A, Brahme A. Therapy optimization based on non-linear uptake of PET tracers versus "linear dose painting". IFMBE Proceedings 2009 (in press).
58. Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 1999;/40:/177-83.
59. Rasey JS, Hofstrand PD, Chin LK, Tewson TJ. Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia. J Nucl Med 1999;/40:/ 1072-9.
60. Wijffels KI, Kaanders JH, Rijken PF, Bussink J, van den Hoogen FJ, Marres HA, et al. Vascular architecture and hypoxic profiles in human head and neck squamous cell carcinomas. Br J Cancer 2000;/83:/674-83.
61. Gagel B, Reinartz P, Dimartino E, Zimny M, Pinkawa M, Maneschi P, et al. pO(2) Polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F] -2-fluoro-2?-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol 2004;/180:/ 616-22.
62. O'Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith- Jones P, Cai S, et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis (N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 2005;/61:/1493-502.
63. Toma-Daşu I, Daşu A, Waites A, Denekamp J, Fowler JF. Theoretical simulation of oxygen tension measurement in the tissue using a microelectrode: II. Simulated measurements in tissues. Radiother Oncol 2002;/64:/109-18.
64. Toma-Daşu I, Daşu A, Karlsson M. The relationship between temporal variation of hypoxia, polarographic measurements and predictions of tumour response to radiation. Phys Med Biol 2004;/49:/4463-75.
65. Daşu A. Treatment planning optimisation based on imaging tumour proliferation and cell density. Acta Oncol 2008;/47:/ 1221-8.